Press release
Chronic Inflammatory Demyelinating Polyneuropathy Market Trends Highlight Clinical Trials, FDA Activity, and Global Market Expansion
Chronic Inflammatory Demyelinating Polyneuropathy
The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market is led by major players such as Grifols, CSL Behring, Octapharma, Baxter, and Kedrion S.p.A., who dominate the immunoglobulin therapy segment. Companies like Bio Products Laboratory Ltd, Shire, and Momenta Pharmaceuticals are expanding their neurology pipelines through innovation and partnerships. Mitsubishi Tanabe Pharma, Teijin Pharma, and Pfizer Inc. are advancing biologic and immunomodulatory treatments.
Download your exclusive sample report today: https://www.datamintelligence.com/download-sample/chronic-inflammatory-demyelinating-polyneuropathy-market?jd
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market M&A & Strategic Collaborations
1. argenx & Zai Lab partnership advancing Vyvgart Hytrulo launch in China
In May 2025, argenx SE and Zai Lab extended their collaboration to support the introduction of Vyvgart Hytrulo, the first subcutaneous FcRn blocker approved for CIDP, into Chinese clinics, aiming to improve treatment convenience and patient access in Greater China.
2. Takeda's GAMMAGARD LIQUID FDA label expansion
In January 2024, Takeda secured FDA approval for GAMMAGARD LIQUID as an IVIG therapy for adult CIDP, with expanded use gaining traction in early 2025 across North America and Europe under national immunoglobulin supply networks.
3. Argenx's Vyvgart Hytrulo boosts clinic readiness
In June 2025, ar¬genx's subcutaneous treatment received momentum in North America following strong real-world outcomes in the ADHERE trial, facilitating new partnerships with infusion centers and health providers for broader rollout.
As per our analysis, these developments underscore the CIDP market's emphasis on therapeutic innovation, label expansions, and cross-border market strategies.
Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/chronic-inflammatory-demyelinating-polyneuropathy-market?jd
Key Growth Drivers & Emerging Opportunities in the CIDP Market
• The rising global prevalence of autoimmune neuropathies is increasing demand for long-term CIDP management solutions.
• Advancements in immunoglobulin and FcRn-targeted therapies (e.g., Vyvgart Hytrulo) are reshaping treatment approaches.
• Improved diagnostic capabilities and earlier disease detection are expanding the eligible patient population.
• Ongoing clinical trials in monoclonal antibodies, subcutaneous therapies, and corticosteroid alternatives are opening new market opportunities.
• Strategic partnerships in emerging markets are enhancing access to CIDP therapies through localized production and distribution.
Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=chronic-inflammatory-demyelinating-polyneuropathy-market?jd
Regional Market Drivers for the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market
North America leads the market due to strong reimbursement systems, high awareness of rare neurological disorders, and early adoption of IVIG and emerging biologics.
Europe benefits from government-funded treatment programs, centralized immunoglobulin supply chains, and robust rare disease surveillance systems.
Asia-Pacific is experiencing rapid growth with increased healthcare access, improving neurology diagnostics, and rising investments in autoimmune disorder research.
Latin America is driven by improving healthcare infrastructure and growing availability of immunoglobulin therapies through international health partnerships.
Middle East & Africa show steady progress due to expanding specialist care facilities and global aid programs supporting rare disease treatment access.
Unlock 360° Market Intelligence with DataM Subscription Services:
https://www.datamintelligence.com/reports-subscription
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Pipeline Analysis For Drug Discovery
✅ Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Competitive Landscape
Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights, and developments to provide swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains, creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Chronic Inflammatory Demyelinating Polyneuropathy Market Trends Highlight Clinical Trials, FDA Activity, and Global Market Expansion here
News-ID: 4104799 • Views: …
More Releases from DataM Intelligence 4Market Research LLP
Rare Earth Elements Market Set to Grow at 9.4% CAGR | 2025 Innovations in Rare E …
The Global Rare Earth Elements Market is growing at a CAGR of 9.4% during the forecast period (2024-2031).
The Rare Earth Elements (REE) market involves the mining, processing, and utilization of 17 metallic elements critical for modern technologies. These materials are essential in electronics, renewable energy, defense systems, and automotive applications. Market growth is driven by rising demand for electric vehicles, wind turbines, and consumer electronics. Supply chain challenges and geopolitical…
United States Automotive Bearing Market to Grow at 6.26% CAGR Through 2031 | Dri …
Global Automotive Bearing market is expected to grow at a CAGR of 6.26% during the forecast period (2024-2031).
The Automotive Bearing market involves components designed to reduce friction and enable smooth rotation in vehicle systems. Bearings are critical in engines, wheels, transmissions, and steering systems. Growing vehicle production, electrification, and demand for fuel efficiency are key drivers. Technological advancements in lightweight, durable, and high-performance bearings support adoption. Expanding automotive aftermarket services…
United States Genomics in Cancer Care Market Set to Surge to USD 51.1B by 2031 a …
Genomics In Cancer Care Market reached USD 13.4 billion in 2022 and is projected to witness lucrative growth by reaching up to USD 51.1 billion by 2031. The Global Genomics in Cancer Care Market is expected to exhibit a CAGR of 18.9% during the forecast period 2024-2031.
The Genomics in Cancer Care market focuses on applying genomic technologies to detect, diagnose, and personalize cancer treatment. Genomic profiling helps identify mutations, biomarkers,…
United States Biodegradable Polymer Market (2024-2031): Driving Eco-Friendly Pac …
The Biodegradable Polymer Market is estimated to reach 20% of CAGR during the forecast period 2024-2031
A biodegradable polymer is a type of polymer that can decompose into natural substances, such as water, carbon dioxide, and biomass, through the action of microorganisms over time. These polymers are designed to break down more quickly than traditional plastics, reducing environmental impact and pollution. Biodegradable polymers are used in various applications, including packaging, agricultural…
More Releases for CIDP
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Growth, Trends, …
Introduction
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare autoimmune disorder characterized by progressive weakness and impaired sensory function in the arms and legs due to damage to the myelin sheath surrounding peripheral nerves. Though uncommon, CIDP significantly affects patient quality of life and requires long-term management, often involving immunotherapy, corticosteroids, and plasma exchange.
Over the past decade, improved diagnostic capabilities, greater awareness of rare neurological diseases, and advancements in immunoglobulin therapies…
CIDP Market Emerging Trends and Growth Prospects 2034
Introduction
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) is a rare, immune-mediated neuropathy characterized by progressive or relapsing weakness, sensory loss, and impaired reflexes due to demyelination of peripheral nerves. Unlike acute Guillain-Barré syndrome, CIDP evolves over at least eight weeks and, without timely treatment, can lead to significant long-term disability. The condition encompasses typical CIDP and several clinical variants (e.g., MADSAM/Lewis-Sumner, DADS, pure motor, pure sensory), each with nuanced diagnostic and therapeutic…
Key Trend Reshaping the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) …
What combination of drivers is leading to accelerated growth in the chronic inflammatory demyelinating polyneuropathy (cidp) market?
The increasing healthcare expenditure is expected to propel the growth of the chronic inflammatory demyelinating polyneuropathy (CIDP) market. Rising healthcare expenditure is a result of increased investments in medical infrastructure, demand for advanced treatments, expanded insurance coverage, and efforts to improve healthcare access. This increased spending facilitates better diagnosis and management of CIDP, a…
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Market Insights and Co …
The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market sector is undergoing significant transformation, with substantial growth and technological advancements expected by 2031. According to a new in-depth market research report, the sector is poised for expansion, driven by various factors such as market size, share, and emerging trends.
This comprehensive report provides key insights into the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market, exploring critical market segmentation and definitions. It highlights the essential…
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Treatment Market 2024-2 …
Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market is an uncommon autoimmune disorder affecting the peripheral nervous system. It manifests through the progressive weakening of muscles and the loss of sensation in extremities. The CIDP treatment market has shown consistent growth and is poised for significant expansion in the forthcoming years. In this comprehensive blog post, we will delve into the current scenario, regulatory framework, market dynamics, supplier landscape, drug distribution model,…
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Market Insights …
The market for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) was valued USD 968 Million in 2017 which is anticipated to reach USD 2,020.6 Million by 2030.
The total number of CIDP patients in the 7MM is projected to reach 55,113 by 2030 from 46,027 in 2019. The U.S. has the highest incidences of CIDP in the 7MM. In 2019, as per the data studied by Report Ocean, there were approximately 29,000…
